fluorouracil has been researched along with sincalide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, Q; Chen, X; Ji, J; Liu, B; Shi, H; Yu, Y; Yuan, F; Zhang, J; Zhu, Z | 1 |
1 review(s) available for fluorouracil and sincalide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for fluorouracil and sincalide
| Article | Year |
|---|---|
Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Topics: Adenocarcinoma; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cell Count; Capecitabine; Cell Line, Tumor; Culture Media; Drug Screening Assays, Antitumor; Endothelial Progenitor Cells; Fluorouracil; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Morphogenesis; Platelet-Derived Growth Factor; Sincalide; Stomach Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |